After promising early results, a sub-study of the DREAMM-5 platform trial is moving forward to its next phase to test a combination of Blenrep (belantamab mafodotin) with nirogacestat in adults with relapsed or refractory multiple myeloma. In addition, two sub-studies will be added to the trial (NCT04126200), sponsored by Blenrep developer GlaxoSmithKline (GSK), to evaluate the combo with standard multiple myeloma therapies. DREAMM-5 is recruiting patients at sites in the U.S., Canada, Europe, Australia, and…
You must be logged in to read/download the full post.
The post Blenrep-nirogacestat Combo Moves to Dose-testing Phase 2 of Trial appeared first on BioNewsFeeds.